secwatch.observer — SEC 8-K summary
======================================

Issuer:     ArriVent BioPharma, Inc. (AVBP)
CIK:        0001868279
Form:       8-K
Filed at:   2026-10-13T10:03:00+00:00
Accession:  0001104659-26-115161
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

ArriVent BioPharma doses first patient in U.S. Phase 1 trial of ARR-002 for ovarian and endometrial cancer
--------------------------------------------------------------------------------

- ArriVent (Nasdaq: AVBP) dosed the first patient in the U.S. Phase 1 trial (NCT07755436) of ARR-002, a MUC16/NaPi2b dual-target tetravalent ADC.
- ARR-002 is a potential first-in-class MUC16/NaPi2b dual-target ADC for ovarian and endometrial cancer; both targets are highly over-expressed in these cancers.
- Stuart Lutzker, President of R&D, said ARR-002 is ArriVent's second ADC to enter the clinic, broadening the pipeline beyond lung and gastrointestinal cancers.
- In August 2026, ArriVent licensed ARR-002 from Shanghai Allist Pharmaceuticals for Greater China, including mainland China, Hong Kong, Macau, and Taiwan, retaining all other rights.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1868279/000110465926115161/0001104659-26-115161-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1868279/000110465926115161/tm2627450d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-115161

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer